5Cho KJ, Hill MM, Chigurupati S, et al. Therapeutic Levels of the Hydroxmethylglutaryl Coenzyme A Reductase Inhibitor Lovastatin Acti- vate Ras Signaling via Phospholipase D2. Mol Cell Biol, 2011,6 : 1110- 1120.
6Wang ZY, Wu YP, Wang HF, et al. Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP tomodulate breast cancer cell motility. Proc Natl Acad Sci USA,2014,111:89-98.
10Lablanche JM, Danchin N, Farnier M, et al. Effects of rosuvastatin and atorvastatin on the apolipopretein B/apolipoprotein A-1 ratio in patients with an acute coronary syndrome: The CENTAURUS trial design. Arch Cardiovasc Dis,2008,101:399-406.
4RIENTO K, RIDLEY AJ. Rocks: multifunctional kinases in cell behaviour [J]. Nat Rev Mol Cell Biol, 2003, 4(6) : 446-456.
5BROWN JH, Del RE DP, SUSSMAN MA. The Rac and Rho hall of fame: a decade of hypertrophic signaling hits [J]. Circ Res, 2006, 98(6): 730-742.
6TATSUNO I, HIRAI A, SAITO Y. Cell-anchorage, cell evtoskelelon and Rho-GTPase family in regulation of cell cycle progression[J]. Prog Cell Cycle Res, 2000, 4: 19-25.
7KATO T, HASHIKABE H, IWATA C, et al. Statin blocks Rho/ Rho-kinase signalling and disrupts the actin cytoskeleton:relationship to enhancement of LPS-mediated nitric oxide synthesis in vascular smooth muscle cells [J]. Biochim Biophys Acta, 2004, 1689(3): 267-272.
8YAMAMOTO T, TAKEDA K, HA'RADA S, et ol. HMG-CoA reductase inhibitor enhances inducible nitric oxide synthase expression in rat vascular smooth muscle cells; involvement of the Rho/Rho kinase pathway[J]. Atherosclerosis, 2003, 166(2): 213-222.
9DOBASHI K, ARAKI S, KUBO K, et al. Hydroxymethylglutaryl-CoA reductase inhibitor inhibits induction of nitric oxide synthase in 3T3-L1 preadipocytes[J]. Life Sci, 2008, 82(1-2): 85-90.
10NAGAOKA T, HEIN TW, YOSHIDA A, et al. Simvastatin elicits dilation of isolated porcine retinal arterioles: role of nitric oxide and mevalonate-rho kinase pathways[J]. Invest Ophthalmol Vis Sci, 2007. 48(2): 825-832.
